Qiagen NV (QGEN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $10.30B
Last updated: Nov 17, 2026 at 11:06 AM ET
Qiagen NV (QGEN) Financials: Revenue, Profit and Cash Flow
Qiagen NV reported revenue of $2.09B for the fiscal year ended Dec 31, 2025, up 5.7% from the year before. That year, net income was $424.88M with a net margin of 20.3%, operating cash flow was $654.33M and free cash flow was $453.28M. The quarter ended Sep 30, 2026 had revenue of $547.87M and net income of $105.66M.
Revenue and Margins
The operating margin was 24.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $1.34B, a compound annual rate of 5.1%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.09B | +5.7% | 61.8% | 24.9% | 20.3% |
| Dec 2024 | $1.98B | +0.7% | 48.9% | 4.9% | 4.2% |
| Dec 2023 | $1.97B | -8.2% | 62.8% | 20.9% | 17.4% |
| Dec 2022 | $2.14B | -4.9% | 64.7% | 24.8% | 19.8% |
| Dec 2021 | $2.25B | +20.4% | 64.4% | 28.0% | 22.8% |
| Dec 2020 | $1.87B | +22.5% | 65.9% | 20.7% | 19.2% |
| Dec 2019 | $1.53B | +1.6% | 65.9% | -1.7% | -2.7% |
| Dec 2018 | $1.50B | +5.9% | 66.6% | 17.8% | 12.7% |
| Dec 2017 | $1.42B | +5.9% | 65.1% | 10.8% | 2.8% |
| Dec 2016 | $1.34B | N/A | 63.1% | 7.4% | 6.0% |
Income Statement
In the fiscal year ended Dec 2025, net income rose 408.3% from the year before. In the quarter ended Sep 2026, net income fell 18.7% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.09B | $1.98B | $1.97B | $2.14B | $2.25B | $1.87B | $1.53B | $1.50B | $1.42B | $1.34B |
| Cost of revenue | $798.50M | $1.01B | $731.62M | $756.96M | $800.84M | $637.63M | $521.16M | $500.89M | $494.98M | $493.34M |
| Gross profit | $1.29B | $967.35M | $1.23B | $1.38B | $1.45B | $1.23B | $1.01B | $1.00B | $922.56M | $844.65M |
| Research and development | $187.52M | $193.49M | $198.51M | $189.86M | $189.96M | $149.07M | $157.45M | $161.85M | $154.08M | $176.13M |
| Operating income | $520.31M | $97.71M | $409.94M | $531.46M | $630.08M | $386.43M | -$26.14M | $266.58M | $153.42M | $98.83M |
| Net income | $424.88M | $83.59M | $341.30M | $423.21M | $512.60M | $359.19M | -$41.45M | $190.38M | $40.39M | $80.40M |
| EBITDA | $717.27M | $368.26M | $688.55M | $779.36M | $895.24M | $715.80M | $227.87M | $499.47M | $380.51M | $308.99M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $547.87M | $535.04M | $492.32M | $540.42M | $532.58M | $533.54M | $483.46M | $521.20M | $501.87M | $496.35M | $458.80M | $509.16M |
| Gross profit | $354.00M | $340.39M | $309.60M | $317.27M | $331.26M | $334.29M | $308.68M | $333.29M | $308.31M | $34.76M | $290.99M | $316.10M |
| Operating income | $151.64M | $132.40M | $116.63M | $153.90M | $129.16M | $121.90M | $115.35M | $119.10M | $112.10M | -$228.44M | $94.95M | $110.61M |
| Net income | $105.66M | $103.40M | $68.04M | $107.83M | $130.04M | $96.25M | $90.76M | $88.32M | $98.06M | -$183.46M | $80.67M | $97.66M |
Balance Sheet
As of Dec 2025, long-term debt of $1.65B exceeded cash and equivalents by $815.42M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.30B | $5.69B | $6.12B | $6.29B | $6.15B | $5.87B | $5.24B | $5.75B | $5.04B | $4.31B |
| Current assets | $2.00B | $1.96B | $2.15B | $2.39B | $2.11B | $1.62B | $1.57B | $2.16B | $1.65B | $1.04B |
| Cash and equivalents | $839.00M | $663.55M | $668.08M | $730.67M | $880.52M | $597.98M | $623.65M | $1.18B | $657.71M | $439.18M |
| Total liabilities | $2.52B | $2.12B | $2.31B | $2.82B | $3.05B | $3.07B | $2.70B | $3.11B | $2.50B | $1.70B |
| Short-term debt | N/A | $77.82M | $610.24M | $411.77M | $869.67M | $65.99M | $303.98M | $503.18M | $1.36M | $999.00K |
| Long-term debt | $1.65B | $1.34B | $921.82M | $1.47B | $1.09B | $1.88B | $1.42B | $1.67B | $1.76B | $1.07B |
| Shareholder equity | $3.78B | $3.57B | $3.81B | $3.47B | $3.10B | $2.80B | $2.54B | $2.63B | $2.54B | $2.61B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $5.94B | $5.89B | $5.78B | $6.30B | $6.55B | $5.82B | $5.55B | $5.69B | $6.27B | $5.58B | $5.81B | $6.12B |
| Total liabilities | $2.47B | $2.53B | $2.45B | $2.52B | $2.90B | $2.32B | $2.14B | $2.12B | $2.74B | $2.18B | $2.21B | $2.31B |
| Cash and equivalents | $805.13M | $768.50M | $646.29M | $839.00M | $1.36B | $733.82M | $638.76M | $663.55M | $972.99M | $533.64M | $513.67M | $668.08M |
| Shareholder equity | $3.47B | $3.36B | $3.33B | $3.78B | $3.65B | $3.51B | $3.41B | $3.57B | $3.53B | $3.41B | $3.60B | $3.81B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 69.3% of operating cash flow. Dividends came to 12.0% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $654.33M | $673.55M | $459.45M | $715.26M | $639.00M | $492.27M | $330.84M | $359.50M | $286.78M | $341.60M |
| Capital expenditures | $201.05M | $167.17M | $162.80M | $149.34M | $206.53M | $304.24M | $274.88M | $150.76M | $124.41M | $93.92M |
| Free cash flow | $453.28M | $506.38M | $296.65M | $565.93M | $432.47M | $188.03M | $55.96M | $208.73M | $162.37M | $247.68M |
| Dividends paid | $54.24M | $0 | $0 | $25.36M | N/A | $622.20M | N/A | $567.28M | $769.66M | N/A |
| Investing cash flow | -$305.28M | -$249.23M | -$87.66M | -$726.76M | -$202.43M | -$443.28M | -$222.28M | -$211.36M | -$464.26M | -$179.06M |
| Financing cash flow | -$178.98M | -$422.90M | -$433.83M | -$125.80M | -$150.37M | -$74.32M | -$639.08M | $360.41M | $387.19M | -$10.60M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $145.63M | $200.69M | $100.63M | $188.13M | $165.02M | $161.44M | $139.74M | $191.51M | $182.35M | $166.62M | $133.08M | $151.37M |
| Capital expenditures | $40.03M | $42.93M | $46.88M | $70.91M | $46.05M | $40.84M | $43.90M | $49.66M | $44.32M | $38.91M | $38.36M | $52.22M |
| Free cash flow | $105.59M | $157.76M | $53.75M | $117.22M | $118.97M | $120.60M | $95.84M | $141.85M | $138.03M | $127.71M | $94.72M | $99.15M |
Frequently Asked Questions About QGEN
What is Qiagen NV's annual revenue?
Qiagen NV reported revenue of $2.09B for the fiscal year ended Dec 31, 2025.
How fast is Qiagen NV's revenue growing?
Revenue was up 5.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -0.8%.
Is Qiagen NV profitable?
Yes. Qiagen NV reported net income of $424.88M for the fiscal year ended Dec 31, 2025, with a net margin of 20.3%.
How much free cash flow does QGEN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $654.33M minus capital expenditures of $201.05M produced free cash flow of $453.28M.
How much debt does Qiagen NV have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $1.65B and cash and equivalents of $839.00M.
QGEN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts